Skip to main content

SQZ Biotechnologies Company (SQZ)

NYSE: SQZ · IEX Real-Time Price · USD
12.28 -0.98 (-7.39%)
Nov 26, 2021 1:00 PM EST - Market closed

Company Description

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions.

Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents.

Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

SQZ Biotechnologies Company
SQZ Biotechnologies Logo
CountryUnited States
IPO DateOct 30, 2020
IndustryBiotechnology
SectorHealthcare
Employees98

Contact Details

Address:
200 Arsenal Yards Boulevard
Watertown, MA 02472
United States
Phone617 758 8672
Websitesqzbiotech.com

Stock Details

Ticker SymbolSQZ
ExchangeNYSE
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$16.00
CIK Code1604477

Key Executives

NamePosition
Dr. Armon R. Sharei Ph.D.Co-Founder, President, Chief Executive Officer, Interim Principal Financial Officer and Director
Lawrence J. KnopfGeneral Counsel and Secretary
Teri LoxamConsultant and Advisor
Micah ZajicChief Business Officer
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCDCo-Founder and Member of Scientific Advisory Board
Richard CapassoChief Accounting Officer
Dr. Howard BernsteinChief Scientific Officer
David FirstChief People Officer

Latest SEC Filings

DateTypeTitle
Nov 19, 2021EFFECTNotice of Effectiveness
Nov 18, 20218-K/ACurrent report
Nov 16, 20213Initial statement of beneficial ownership of securities
Nov 10, 2021S-3Registration statement under Securities Act of 1933
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 4, 20218-KCurrent report
Oct 26, 20218-KCurrent report
Sep 13, 20218-KCurrent report
Sep 2, 20218-KCurrent report
Aug 9, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
View All SEC Filings